Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.52 |
| ▸ | CCR2 | P41597 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 4/20 | 0.45 |
| ▸ | HTR2A | P28223 | 4/20 | 0.45 |
| ▸ | HTR7 | P34969 | 4/20 | 0.45 |
| ▸ | HTR6 | P50406 | 4/20 | 0.45 |
| ▸ | GHSR | Q92847 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1575937 | 0.81 | CA2 (0.61) | CA2TPSAB1CCR2HDAC1DRD2 | |
| SCHEMBL8798934 | 0.80 | CA2 (0.51) | CA2TPSAB1CCR2HDAC1DRD2 | |
| Hydrochloric Acid SCHEMBL6369828 | 0.80 | TPSAB1 (0.61) | CA2TPSAB1CCR2HDAC1DRD2 | |
| SCHEMBL4425071 | 0.79 | CA2 (0.47) | CA2TPSAB1CCR2HDAC1DRD2 | |
| SCHEMBL16597959 | 0.78 | CA2 (0.61) | CA2TPSAB1CCR2HDAC1DRD2 | |
| SCHEMBL19559025 | 0.78 | CA2 (0.59) | CA2TPSAB1CCR2HDAC1DRD2 | |
| SCHEMBL7916539 | 0.77 | CA2 (0.56) | CA2TPSAB1CCR2HDAC1GHSR | |
| SCHEMBL4188720 | 0.77 | CCR2 (0.64) | CA2TPSAB1CCR2HDAC1GHSR | |
| SCHEMBL12157405 | 0.75 | CA2 (0.67) | CA2CCR2HDAC1GHSRAKR1B1 | |
| SCHEMBL743918 | 0.75 | CA2 (0.67) | CA2TPSAB1CCR2HDAC1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7635683-B2 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-20080317712-A1 | ARYLPIPERIDINYL AND ARYLPYRROLIDINYL TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-12-25 | — | — | US | disclosed |
| US-20080032936-A1 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080317712-A1 | ARYLPIPERIDINYL AND ARYLPYRROLIDINYL TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS | PREP, DNPEP, CTSC | CA2 2971/4885TPSAB1 348/4885CCR2 1013/4885 |
| US-20080032936-A1 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | VIP, CTSC, PREP | CA2 1722/4885TPSAB1 196/4885CCR2 1946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.